Capsule Summary Slidesets

Share

Program Content

Activities

  • DREAMM 7 Belantamab Combo
    DREAMM-7 Efficacy Update: Belantamab Mafodotin Plus Bortezomib, Dexamethasone vs Daratumumab Plus Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2024

    Expires: December 10, 2025

  • Mezigdomide Plus Vd or Kd for RRMM
    Mezigdomide Plus Vd or Kd in Relapsed/Refractory Multiple Myeloma: Updated Results From the CC-92480-MM-002 Phase I/II Trial
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

    Expires: December 11, 2025

  • Arlocabtagene Autoleucel
    Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-cell Therapy, in Heavily Pretreated Multiple Myeloma: Updated Phase I Study Results
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

    Expires: December 11, 2025

  • IFM2017-03: Dara Len in Frail ND MM
    IFM2017-03: Phase III Trial of Daratumumab Plus Lenalidomide Without Long-term Dexamethasone vs Lenalidomide and Dexamethasone in Frail Patients With Newly Diagnosed MM
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2024

    Expires: December 11, 2025

  • MajesTEC 4
    EMN30/MajesTEC-4: Safety Run-in Data From Phase III Trial of Teclistamab ± Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma After ASCT
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

    Expires: December 12, 2025

  • AQUILA Daratumumab
    AQUILA: Primary Results From the Phase III Trial of Daratumumab vs Active Monitoring for High-Risk Smoldering Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

    Expires: December 12, 2025

Provided by

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation